BAT2606 vs Depemokimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: IL-5 · full Asthma pipeline

BAT2606

Developed by Bio-Thera Solutions

Phase 1 in Asthmamonoclonal antibody
Partial signal

NCT05576454 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Cmax (Day1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 22, 29, 43, 57, 71, 85, 99, 113); AUC0-∞ (Day1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 22, 29, 43, 57, 71, 85, 99, 113): In 207 subjects enrolled and randomized, the 90% confidence intervals of the geometric mean ratios of maximum concentration and area under the curve from time 0 to infinity were within 80.00%-125.00%. (met)

Result source: NCT05576454

Depemokimab

Marketed by GlaxoSmithKline

Approved in Asthmamonoclonal antibody
Partial signal

NCT04718389 · Phase 3 · completed

This was a large randomized, double-blind, active-controlled trial comparing depemokimab with mepolizumab or benralizumab, using the clinically meaningful primary endpoint of annualized clinically significant asthma exacerbations. The primary results were 0.57 versus 0.49 exacerbations per participant-year (rate ratio 1.16, 95% CI 0.98–1.38; p=0.079), but the record does not provide the non-inferiority margin, so it is not possible to confirm that the primary endpoint was met.

Next expected readout: February 2027 · NCT07828327 (registry estimate)

Reported efficacy

Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58) (met)

Result source: NCT04719832

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBAT2606Depemokimab
Severe exacerbations, annualised rate—Not reported0.6 vs 1.1−0.5 vs placebowk 52 · n 252NCT04718103
1 other result
  • 0.5 vs 1.1 wk 52 · n 249 · Phase 3 · primary NCT04719832
Trough FEV1, change—Not reported0.2 vs 0.2+0.1 vs placebowk 52 · n 239NCT04718103
ACQ-5, change—Not reported-0.8 vs -0.7−0.1 vs placebowk 52 · n 246NCT04718103
1 other result
  • -0.8 vs -0.8 wk 52 · n 241 · Phase 3 · secondary NCT04719832
OCS dose reduction—Not reported—Trial running · NCT06979323

Severe exacerbations, annualised rate

BAT2606
—Not reported
Depemokimab
0.6 vs 1.1−0.5 vs placebowk 52 · n 252NCT04718103
1 other result
  • 0.5 vs 1.1 wk 52 · n 249 · Phase 3 · primary NCT04719832

Trough FEV1, change

BAT2606
—Not reported
Depemokimab
0.2 vs 0.2+0.1 vs placebowk 52 · n 239NCT04718103

ACQ-5, change

BAT2606
—Not reported
Depemokimab
-0.8 vs -0.7−0.1 vs placebowk 52 · n 246NCT04718103
1 other result
  • -0.8 vs -0.8 wk 52 · n 241 · Phase 3 · secondary NCT04719832

OCS dose reduction

BAT2606
—Not reported
Depemokimab
—Trial running · NCT06979323
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

BAT2606
In 207 subjects enrolled and randomized, the 90% confidence intervals of the geometric mean ratios of maximum concentration and area under the curve from time 0 to infinity were within 80.00%-125.00%. NCT05576454 · Phase 1 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. BAT2606: 0 of 4 rows · Depemokimab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDepemokimab
Dropout rate
11.2%100mg SCa
NCT04718389 · Phase 3 · combination · Asthma · phase 3
show 13 more results
11.4%
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
8.5%
NCT04719832 · Phase 3
5.6%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
7%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
1.4%Depemokimab Via Autoinjector
NCT05602025 · Phase 1 · registry result, not featured evidence
1.4%Depemokimab Via SSD
NCT05602025 · Phase 1 · registry result, not featured evidence
0%100mg
NCT05140200 · Phase 1 · registry result, not featured evidence
10%300mg
NCT05140200 · Phase 1 · registry result, not featured evidence
—100mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—300mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—30mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—10mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—2mg
NCT03287310 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
0.8%100mg SCa
NCT04718389 · Phase 3 · combination · Asthma · phase 3
show 13 more results
0.4%
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
0%
NCT04719832 · Phase 3
0.2%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
0.5%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
—Depemokimab Via Autoinjector
NCT05602025 · Phase 1 · registry result, not featured evidence
—Depemokimab Via SSD
NCT05602025 · Phase 1 · registry result, not featured evidence
—100mg
NCT05140200 · Phase 1 · registry result, not featured evidence
—300mg
NCT05140200 · Phase 1 · registry result, not featured evidence
—100mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—300mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—30mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—10mg
NCT03287310 · Phase 1 · registry result, not featured evidence
—2mg
NCT03287310 · Phase 1 · registry result, not featured evidence
Serious AEs
9.4%100mg SCa
NCT04718389 · Phase 3 · combination · Asthma · phase 3
show 13 more results
7.6%
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
6%
NCT04719832 · Phase 3
9.1%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
10%100 mg SC
NCT05243680 · Phase 3 · registry result, not featured evidence
2.9%Depemokimab Via Autoinjector
NCT05602025 · Phase 1 · registry result, not featured evidence
0%Depemokimab Via SSD
NCT05602025 · Phase 1 · registry result, not featured evidence
0%100mg
NCT05140200 · Phase 1 · registry result, not featured evidence
0%300mg
NCT05140200 · Phase 1 · registry result, not featured evidence
0%100mg
NCT03287310 · Phase 1 · registry result, not featured evidence
0%300mg
NCT03287310 · Phase 1 · registry result, not featured evidence
0%30mg
NCT03287310 · Phase 1 · registry result, not featured evidence
0%10mg
NCT03287310 · Phase 1 · registry result, not featured evidence
0%2mg
NCT03287310 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
100mg SCa
nasopharyngitis 20.6%
covid-19 18.3%
upper respiratory tract infection 11.4%
NCT04718389 · Phase 3 · combination · Asthma · phase 3
show 13 more results
covid-19 14.3% (placebo 14.7%)
nasopharyngitis 13.1% (placebo 20.9%)
upper respiratory tract infection 8.4% (placebo 4.7%)
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
covid-19 20.4% (placebo 20.5%)
nasopharyngitis 11.6% (placebo 18.9%)
upper respiratory tract infection 10% (placebo 10.6%)
NCT04719832 · Phase 3
100 mg SC
nasopharyngitis 13.8%
upper respiratory tract infection 10.7%
covid-19 6.7%
NCT05243680 · Phase 3 · registry result, not featured evidence
100 mg SC
upper respiratory tract infection 11.9%
nasopharyngitis 10%
covid-19 7.1%
NCT05243680 · Phase 3 · registry result, not featured evidence
headache 8.6%
injection site swelling 5.7%
abdominal pain 4.3%
NCT05602025 · Phase 1 · registry result, not featured evidence
headache 10%
injection site bruising 4.3%
nausea 4.3%
NCT05602025 · Phase 1 · registry result, not featured evidence
100mg
blood creatine phosphokinase increased 80%
blood uric acid increased 30%
neutrophil count increased 20%
NCT05140200 · Phase 1 · registry result, not featured evidence
300mg
albumin urine present 50%
blood creatine phosphokinase increased 40%
blood uric acid increased 40%
NCT05140200 · Phase 1 · registry result, not featured evidence
100mg
nasopharyngitis 55.6% (placebo 16.7%)
headache 33.3% (placebo 0%)
back pain 22.2% (placebo 8.3%)
NCT03287310 · Phase 1 · registry result, not featured evidence
300mg
headache 33.3% (placebo 0%)
nasopharyngitis 33.3% (placebo 16.7%)
epistaxis 16.7% (placebo 0%)
NCT03287310 · Phase 1 · registry result, not featured evidence
30mg
nasopharyngitis 33.3% (placebo 16.7%)
arthropod sting 22.2% (placebo 0%)
dry skin 22.2% (placebo 0%)
NCT03287310 · Phase 1 · registry result, not featured evidence
10mg
dyspepsia 33.3% (placebo 0%)
rib fracture 33.3% (placebo 0%)
seasonal allergy 33.3% (placebo 16.7%)
NCT03287310 · Phase 1 · registry result, not featured evidence
2mg
nasopharyngitis 33.3% (placebo 16.7%)
diarrhoea 16.7% (placebo 0%)
headache 16.7% (placebo 0%)
NCT03287310 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 12 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Depemokimab

Severe Exacerbation Rate Annualized 0.57 per year @ 52wk100mg SC
event rate · per year
No placebo or comparator arm
NCT04718389 · Phase 3 · combination · Asthma · phase 3
SGRQ Total -0.69 score100mg SC
absolute change · score
No placebo or comparator arm
NCT04718389 · Phase 3 · combination · Asthma · phase 3
ACQ-5 0.03 score100mg SC
absolute change · score
No placebo or comparator arm
NCT04718389 · Phase 3 · combination · Asthma · phase 3
FEV1 Trough -0.014 L100mg SC
absolute change · L
No placebo or comparator arm
NCT04718389 · Phase 3 · combination · Asthma · phase 3
Severe Exacerbation Rate Annualized 0.56 vs 1.08 placebo per year @ 52wk
event rate · per year
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
0.46 vs 1.11 placebo per year @ 52wk
NCT04719832 · Phase 3
SGRQ Total -14.8 vs -12.49 placebo score @ 52wk
absolute change · score
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
-13.03 vs -9.67 placebo score @ 52wk
NCT04719832 · Phase 3
ACQ-5 -0.81 vs -0.7 placebo score @ 52wk
absolute change · score
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
-0.82 vs -0.77 placebo score @ 52wk
NCT04719832 · Phase 3
FEV1 Trough 0.24 vs 0.184 placebo L @ 52wk
absolute change · L
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
ANSD Weekly Mean -1.18 vs -0.97 placebo score @ 52wk
absolute change · score
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
-1.39 vs -1.3 placebo score @ 52wk
NCT04719832 · Phase 3
ADSD -1.13 vs -0.93 placebo score @ 52wk
absolute change · score
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
show 1 more result
-1.33 vs -1.25 placebo score @ 52wk
NCT04719832 · Phase 3
Exacerbation Hospitalization ED Rate Annualized 0.05 vs 0.11 placebo per year @ 52wk
event rate · per year
NCT04718103 · Phase 3 · monotherapy · Asthma · phase 3
FEV1 0.16 vs 0.16 placebo L @ 52wk
absolute change · L
NCT04719832 · Phase 3

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT2606's landscape · Depemokimab's landscape